

CURRICULUM VITAE

Update Jan 9,2013

**MAURICE McGREGOR. OQ OC****M.B., BCh., M.D., FRCP(C), FRCP(London), FACP, FACC.****TIME LINES** [References in brackets refer to the publications listed below]

1936-42. **Medical School**, University of the Witwatersrand (WITS) Johannesburg

1942-46. **Military Service**. S.A.Med.Corps. Africa / Italy. British 8<sup>th</sup> and US 5<sup>th</sup> Armies.

1946. **Internship, Residency Training**, Johannesburg Hospital. MD thesis: The Radiological Diagnosis of Basilar Impression, which introduced a measurement still used in radiology, referred to as "McGregor's Line"[3] .

1948-50. **Cardiology Training** ,London, Hammersmith, National Heart, and Brompton hospitals under Dr Paul Wood . (Trained in glassblowing, useful in preparing research apparatus at that time). Invented and constructed an angiographic cassette changer [4], and injection device [7] which remained in use at the Brompton Hospital for next 10 years. Took advantage of early open heart surgery to make recordings from the surface of the beating human heart in order to better understand the origin of the electrocardiographic changes associated with right ventricular hypertrophy [ 6] .

1950-57. **Lecturer**, WITS University and **Physician**, Johannesburg Hospital. Published descriptions of Ebstein's anomaly [8], Tetralogy of Fallot [9], Pulmonary valve incompetence [32], Truncus Arteriosus [35], Coarctation of the aorta[10] and Mitral valve disease [12,19], the effect of oxygen on pulmonary artery pressure [14], the first description of an association between electrical alternans and pericardial effusion [20], and the cardiovascular physiology of the giraffe [40]. ( With introduction of Apartheid became increasingly involved in politics. Joined the Liberal Party, a multiracial party that was rapidly banned).

1955. **Harvard School of Public Health**. Boston. Studies on the physiology of the lung and heart [ 23-30, 41] .

1957-67. **Cardiologist** at Montréal Children's Hospital and the Royal Victoria Hospital, and **Assoc Prof**, McGill University. Co-Director, the Joint Cardiorespiratory Unit [42-90], subsequently renamed the Meakin's Christie Research Laboratories.

1967-72. **Dean** of Medicine, McGill. A turbulent period, including a student "revolution", Québec's Révolution Tranquille , letterbox bombs in Westmount, Operation McGill , a mass demonstration promoting *McGill Francais* , a strike of physicians against the introduction of Medicare [91] ended by the October Crisis and declaration of a "State of Emergency" in Québec.

1972-3. **Vice Principal** Health, McGill University and **Cardiologist in Chief** at the Royal Victoria Hospital.

1973. **Bethune Exchange** Professor with "Pekin" Medical college, lecturing in Beijing, Guangzhou, and Shanghai.

1974-9. **Physician in Chief**, the Royal Victoria Hospital.

- 1979-84. **Cardiologist**, the Royal Victoria Hospital. Publications in biomedical [92-96,99,100-102,104,106-8,110,112], and health policy research [95,97,98,103,105,109].
- 1984-86. **Dean** of Medicine, Univ of the Witwatersrand, Johannesburg, [111,113,115,117,119].
1987. **Prof Emeritus**, McGill University. Senior Physician, Royal Victoria Hospital.
- 1987-94. **Founding Président**. The Conseil d'évaluation des technologies de la santé du Québec (CETS) [122-35].
- 1994-98. **Chair** of the Steering Committee for the development of Canadian Clinical Practice Guidelines for the Care and Treatment of Breast Cancer [136].
- 2000-03. **Member**, Grants Committee on Health Policy and Systems Management, CIHR.
- 2000-2012. **Founding Chair** Technology Assessment Unit, MUHC. [138-46, 151].
- 2007-09. **Member**, International Expert Panel on Economic Evaluation of the German Institute for Quality in Health Care, Germany [151].
- 2009- 2010. **Member**, Steering Committee on Organ and Tissue Donation and Transplantation, Canadian Blood Services.

### **HONORARY INSTITUTIONAL SERVICE**

- |         |   |
|---------|---|
| 2000-08 | Governor, Montreal Diet Dispensary                              |
| 1999-   | Governor, Portage Project, Chair, Research Committee.           |
| 1994-05 | Editorial Board, J. Quality in Clinical Practice                |
| 1990-97 | Board of Governors, Royal Victoria Hospital                     |
| 1989-90 | Member, Centre Québécois de coordination sur le SIDA            |
| 1979-84 | Editorial Board, Circulation                                    |
| 1979-83 | Board of Governors, Queen Elizabeth Hospital                    |
| 1972-74 | Member, Conseil de la politique scientifique du Québec          |
| 1974-77 | Vice-Pres., Montreal Neurological Hospital                      |
| 1973-75 | Member, Board of Governors, Lakeshore General Hospital          |
| 1972-74 | President, Montreal Joint Hospitals Institute (RVH,MGH,MCH,MNH) |
| 1970-77 | Board of Governors, Montreal Joint Hospitals Institute          |
| 1967-77 | Board of Governors, Montreal Neurological Hospital              |
| 1967-77 | Board of Governors, Royal Victoria Hospital                     |
| 1967-72 | Board of governors, Montreal General Hospital                   |

### **HONOURS**

- |      |   |
|------|---|
| 2012 | Order of Canada   |
| 2011 | The Dr Jill M Sanders Award of Excellence in HTA  |
| 2008 | Cardiologue émérité 2008. l'Association des Cardiologues du Québec.                                   |
| 2006 | Prix « Maurice McGregor ». Agence d'évaluation des technologies et des modes d'intervention en santé. |
| 2001 | Chevalier de l'Ordre national du Québec.  |
| 2001 | 2001 Award, Quebec Region, Royal College of Physicians of Canada                                      |
| 1992 | Physician-in-Chief Award, Royal Victoria Hospital   |
| 1987 | Professor Emeritus – McGill University  |
| 1979 | Honorary Degree. MD Honoris Causa – University of Witwatersrand                                       |
| 1974 | Ray F. Farquharson Memorial Lecturer, University of Toronto   |
| 1969 | Fellow, Royal College of Physicians of London   |
| 1968 | Honorary Fellowship, Royal College of Physicians of Canada  |

## **PUBLICATIONS**

### **249 Peer reviewed articles, book chapters, reports, listed below:**

#### **Refereed Papers**

1. McGregor M. Electrical Alternans. *Electrocardiographic Case book XVIII. Clin Proc* 1946;5:404-8.
2. McGregor M. A case of hereditary haemorrhagic telangiectasia. *Clin Proc* 1947;6:94-8.
3. McGregor M. The significance of certain measurements of the skull in the diagnosis of basilar impression. *Br J Radiol* 1948;21:171-81.
4. McGregor M. Angiocardiography: a new cassette changer. *Br J Radiol* 1949;22:459-61.
5. Wood P, McGregor M, Magidson O, Whittaker W. The effort test in angina pectoris. *Br Heart J* 1950; 12:363-71.
6. McGregor M. The genesis of the electrocardiogram of right ventricular hypertrophy. *Br Heart J* 1950;12:351-9.
7. McGregor M., Angiocardiography: an aid to technique. *Br J Radiol* 1951;24:28 (letter).
8. Van Lingen B, McGregor M, Meyer MJ, Jacobs HD, Braudo JL, Bothwell TH, Elliott GA Kaye J. Clinical and cardiac catheterisation findings compatible with Ebstein's anomaly of the tricuspid valve. *Am Heart J* 1952;43:77-8.
9. McGregor M, Van Lingen B, Bothwell TH, Kaye J, Greenstein J, Whidbourne J, Braudo JL, Jacobs HD, Elliott GA. Fallot's tetralogy: its differentiation from pulmonic stenosis with intact ventricular septum and an inter-auricular communication (Fallot's trilogy). *S A J Clin Sci* 1952;3:154-70.
10. McGregor M, Medalie M. Coarctation of the aorta. *Br Heart J* 1952;14:531-3.
11. Bothwell TH, Van Lingen B, Whidborne J, Kaye J, McGregor M, Elliott GA. Patent ductus arteriosus with partial reversal of the shunt. *Am Heart J* 1952;44:360-71.
12. Kaye J, Meyer B, Van Lingen B, McGregor M, Braudo JL. The radiological diagnosis of mitral valve disease. *Br J Radiol* 1953;26:242-51.
13. Bradlow BA, McGregor M, Bothwell TH, Zion MM. The effect of thyroid extract in hypertension. *S A Med J* 1953;27:717-21.
14. McGregor M, Bothwell TH, Zion MM, Bradlow BA. The effects of oxygen breathing on the pulmonary circulation in cases of mitral stenosis. *Am Heart J* 1953;46:187-94.
15. McGregor M. Clinical diagnosis in congenital heart disease. *The Leech* 1953;23:59-63.
16. Becklake MR, McGregor M, Goldman HI, Braudo JL. A study of the effects of physiotherapy on chronic hypertrophic pulmonary emphysema using lung function tests. *Dis Chest* 1954;26:1-12.
17. Becklake MR, McGregor M, Goldman HI. The effects of pneumo-peritoneum on lung function In pulmonary emphysema. *Thorax* 1954;9:222-5.
18. McGregor M, Zion MM, Bothwell TH. Oral hydergine in essential hypertension. *S A Med J* 1954;28:292-4.
19. McGregor M. The diagnosis of mitral incompetence in the presence of mitral stenosis. *Acta Med Scand* 1955; 152(Suppl 3 06)11:111-24.
20. McGregor M, Baskind B. Electrical alternans in pericardial effusion. *Circulation* 1955;I 1:837-43.
21. McGregor M, Segal N. The Rauwolfia alkaloids in the treatment of hypertension. *Br Heart J* 1955;17:391 - 6.
22. Becklake MR, Griffith SB, McGregor M, Goldman HI, Shreve JP. Oxygen dissociation curves in sickle cell anaemia and in subjects with the sickle cell trait. *J Clin Invest* 1955;34:751-5.
23. McGregor M, Rappaport MB, Sprague HB, Friedlich AL. The calibration of heart sound intensity. *Circulation* 1956;13:252-6.
24. Borst HG, McGregor M, Whittenburger JL, Burglund E. The influence of pulmonary arterial and left atrial pressure on pulmonary vascular resistance. *Circ Res* 1956;4:393-9.

25. McGregor M, Rappaport MB. Problems of ballistocardiography. SAMed J 1957;393-9.
26. McGregor M, Rappaport MB, Duff JH. The ballistocardiographic effects of acute vena caval ligation. S A J Med Sci 1957;22:137-40.
27. Melik R, McGregor M. Reserpine and extracellular fluid volume. N Engl J Med 1957; 256: 1000-2.
28. Borst HG, Berglund E, McGregor M. The effects of pharmacologic agents on the pulmonary circulation in the dog. Studies on epinephrine, norepinephrine, 5-hydroxytryptamine, acetylcholine, histamine and aminophylline. J Clin Invest 1957;36:669-75.
29. Borst HG, Whittenberger JL, Berglund E, McGregor M. The effects of unilateral hypoxia and hypercapnia on pulmonary blood flow distribution in the dog. Am J Physiol 1957;36:1708-14.
30. Borst HG, Berglund E, Whittenberger JL, Mead J, McGregor M, Collier C. The effect of pulmonary vascular pressures on the mechanical properties of the lungs in anaesthetized dogs. J Clin Invest 1957;36:1708-14.
31. Kamener R, Becklake MR, Goldman HI, McGregor M. Hyperinflation and lung function following surgery. S A J Med Sci 1957;22:156.
32. Segel N, Van Lingen B, Resnekov V, McGregor M. Isolated congenital pulmonary incompetence. S A Med J 1957;31:1157-9.
33. Kamener R, Becklake MR, Goldman HI, McGregor M. Respiratory function following segmental resection of the lung for bronchiectasis. Am Rev Tuberc & Pulm Dis 1958;77(2):209.
34. Theron JC, Zwi S, McGregor M. A respiratory valve of low resistance. Lancet 1958;1:415-6.
35. Goldberg MG, McGregor M. Persistent truncus arteriosus. Am Heart J 1958;55:360-5.
36. Sandler A, McGregor M. Parenteral magnesium sulphate in coronary artery disease. S A Med J 1958;32:697-9.
37. McGregor M, Davenport HT, Jagier W, Sekelj P, Gibbons JE, Demers PP. The cardiovascular effects of halothane in normal children. Br J Anaesth 1958;30:398-408.
38. McGregor M. The value of an index of maximal expiratory force in the interpretation of tests of maximal ventilatory capacity. Am Rev Tuberc 1958;78:692-6.
39. Zwi S, Theron JC, McGregor M, Becklake MR. The influence of instrumental resistance on the maximum breathing capacity. Dis Chest 1959;36:361-8.
40. Goetz RH, Warren JJ, Gauer OH, Patterson JL Jr, Keen EM, McGregor M. Circulation in the giraffe. Circ Res 1960;8:1049-58.
41. Whittenberger JL, McGregor M, Berglund E, Borst HG. Influence of state of inflation of the lung on pulmonary vascular resistance. J App Physiol 1960; 15:87 8-82.
42. Anderson N, Sekelj P, McGregor M. The transmission of red and infra-red light through the human ear. IRE Transactions on Biomedical Electronics. Biomed Electronics 1961;8:134-5.
43. Sekelj P, McGregor M. Estimation of cardiac output in man using an ear oximeter and coomassie blue dye. IRE Transactions on Biomedical Electronics. Biomed Electronics 1961;8:127-33.
44. McGregor M, Becklake MR. The relationship of oxygen cost of breathing to respiratory mechanical work and respiratory force. J Clin Invest 1961;40:971-80.
45. Jegier E, Sekelj P, Davenport HT, McGregor M. Cardiac output and related haemodynamic data in normal children and adults. Can J Biochem & Physiol 1961;39:1747-53.
46. McGregor M, Sekelj P, Adam W. Measurement of cardiac output in man by dye dilution curves using simultaneous ear oximeter and whole blood cuvette techniques. Circ Res 1961;9:1083-8.
47. McGregor M, Adam W, Sekelj P. Influence of posture on cardiac output and minute ventilation during exercise. Circ Res 1961;9:1089-92.
48. McGregor M, Donevan RE, Anderson NM. Influence of carbon dioxide and hyperventilation on cardiac output in man. J Appl Physiol 1962; 17:933 -7.
49. Kinsella D, Troup W, McGregor M. Studies with a new coronary vasodilator drug: persantine. Am Heart J 1962;63:146-51.
50. Donevan RE, Anderson NM, Sekelj P, Papp O, McGregor M. Influence of voluntary hyperventilation on cardiac output. J Appl Physiol 1962;17:487-91.

51. Becklake MR, Varvis CJ, Pengelly LD, Kenning S, McGregor M, Bates DV. Measurement of pulmonary blood flow during exercise using nitrous oxide. *J Appl Physiol* 1962; 17:579-86.
52. Bousvaros GA, Palmer WH, Seke1j P, McGregor M. Comparison of central and peripheral injection sites in the estimation of cardiac output by dye dilution curves. *Circ Res* 1963; 12:317-21.
53. Auld PAM, Johnson AL, Gibbons JE, McGregor M. Changes in pulmonary vascular resistance in infants and children with left-to-right intracardiac shunts. *Circulation* 1963;27:257-60.
54. Jegier W, Sekelj P, Auld PAM, Simpson R, McGregor M. Relationship between cardiac output and body size. *Br Heart J* 1963;25:425-30.
55. Auld PAM, Gibbons JE, McGregor M. Vasomotor tone in the pulmonary vascular bed in patients with left-to-right shunts. *Br Heart J* 1963;25:25 7-61.
56. Sosa JA, McGregor M. Prenylamine in angina pectoris. *Can Med Assoc J* 1963;89:248-51.
57. Klassen GA, Rubin JW, McGregor M. The effect of synthetic oxytocin in impaired atrioventricular conduction. *Am J Cardiol* 1963; 12:523-6.
58. Johnson AL, Klassen GA, McGregor M, Dobell ARC. Long-term electrical stimulation of the heart in Stokes-Adams disease. *Can Med Assoc J* 1963;89:683-6.
59. Peretz DI, McGregor M, Dossetor JB. Lactic acidosis: a clinically significant aspect of shock. *Can Med Assoc J* 1964;90:673-5.
60. Zsoter T, Farn WM, McGregor M. The effect of lipernia on peripheral blood flow. *Can Med Assoc J* 1964;90:1203-5.
61. Davenport HT, Auld PAM, Seke1j P, Jegier W, McGregor M. Hypercarbia during light Halothane anaesthesia with neuromuscular block. *Anaesth* 1964;25:307-11.
62. Newhouse MT, Becklake MR, Macklem PT, McGregor M. Effect of alternations in end-tidal C0<sub>2</sub> tensions on flow resistance. *J Appl Physiol* 1964;19:745-9.
63. Fam WM, McGregor M. Effect of coronary vasodilator drugs on retrograde flow in areas of chronic myocardial ischemia. *Circ Res* 1964;15:355-65.
64. McGregor M, Klassen GA. Observations on the effect of heart rate on cardiac output in patients with complete heart block at rest and during exercise. *Circ Res* 1964;11:215.
65. Oriol A, Palmer WH, Nakhjavan FK, McGregor M. Prediction of left atrial pressure from the second sound-opening snap interval. *Am J Cardiol* 1965;16:184-8.
66. Newhouse MT, McGregor M. Long-term Dipyridamole therapy of angina pectoris. *Am J Cardiol* 1965;16:234-7.
67. Dawson A, Kaneko K, McGregor M. Regional lung function in patients with mitral stenosis studied with Xenon 133 during air and oxygen breathing. *J Clin Invest* 1965;44:999-1008.
68. Goetz RH, Doyle JT, McGregor M. Cardiorespiratory dynamics in the ox and giraffe, with comparative observations on man and other animals. *Ann New York Acad Sci* 1965;127:393-413.
69. Peretz DI, Scott FIM, Duff J, Dossetor JB, MacLean LD, McGregor M. The significance of lactic acidemia in the shock syndrome. *Annals New York Acad Sci* 1965; 119:1133 -41.
70. Bousvaros GA, Campbell JE, McGregor M. Haemodynamic effects of Dipyridamole at rest and during exercise in healthy subjects. *Br Heart J* 1965;28:331-4.
71. Scott HM, Peretz DI, Duff JH, MacLean LD, McGregor M. Effect of prolonged infusion of Isoproterenol on plasma volume, blood lactate and pyruvate in the dog. *Can J Pharmacol & Physiol* 1966;44:29-37.
72. Smith HJ, Bousvaros GA, McGregor M. Failure of acute digitalization to influence exercise tolerance in angina pectoris. *BMJ* 1966; 1 (May 28):1337-8.
73. Hoeschen RJ, Bousvaros GA, Klassen GA, Fam WM, McGregor M. Haemodynamic effects of angina pectoris, and of nitroglycerin in normal and anginal subjects. *Br Heart J* 1966;28:221-30.
74. Nakhjavan FH, Palmer WH, McGregor M. Influence of respiration on venous return in pulmonary emphysema. *Circulation* 1966;33:8-16.
75. Palmer WH, Fam WM, McGregor M. The effect of coronary vasodilation (Dipyridamole-induced) on the myocardial distribution of tritiated water. *Can J Physiol and Pharmacol* 1966;44:777-82.

76. Dagenais GR, Oriol A, McGregor M. Haemodynamic effects of carbohydrate and protein meals in man: rest and exercise. *J Appl Physiol* 1966;21:1157-62.
77. McGregor M, Fam WM. Regulation of coronary blood flow. *Bull New York Acad Med* 1966;42:940-50.
78. McGregor M. Pharmacology of anti-anginal agents. *Med Coll Virginia Quarterly* 1967;3(2):77-9
79. Fam WM, Levene D, McGregor M. Effect of Alpha and Beta adrenergic stimulators on the total coronary vascular resistance and on resistance in the large superficial coronary vessels. *Fed Proc* 1967;26:771.
80. Morch JE, Smith HJ, McGregor M. Quantitation of mitral regurgitation by constant infusion of Xenon 133. *Circulation* 1967;35:501-8.
81. Smith JH, Oriol A, Morsch J, McGregor M. Haemodynamic studies in cardiogenic shock: treatment with Isoproterenol and Metaraminol. *Circulation* 1967;35:1084-91.
82. Oriol A, Sekelj P, McGregor M. Limitations of indicator dilution methods in experimental shock. *J Appl Physiol* 1967;23:605-8.
83. Sekelj P, Oriol A, Anderson NM, Morsch J, McGregor M. Measurement of indocyanine green using a cuvette oximeter. *J Appl Physiol* 1967;23:114-20.
84. Oriol A, McGregor M. Indicator-dilution methods in estimation of cardiac output in clinical shock. *Am J Cardiol* 1967;20:826-30.
85. Oriol A, Sekelj P, McGregor M. Limitations of indicator-dilution methods in experimental shock. *J Appl Physiol* 1967;23:605-8.
86. Oriol A, Anthonisen N, McGregor M. Limitations of indicator dilution methods in the estimation of cardiac output in chronic lung disease. *Am Heart J* 1968;75:589-94.
87. Fam WM, McGregor M. Effect of nitroglycerin and dipyridamole on regional coronary resistance. *Circ Res* 1968;22:649-59.
88. Brandi G, Fam WM, McGregor M. Measurement of coronary flow in local areas of myocardium using Xenon 133. *J Appl Physiol* 1968;24:446-50.
89. Fam WM, McGregor M. Pressure flow relationships in the coronary circulation. *Circ Res* 1969;25:293-301.
90. Brandi G, McGregor M. Intramural pressure in the left ventricle of the dog. *Cardiol Res* 1969;3:472-5.
91. McGregor M. Strike and the Physician. *Can Med Assoc J* 1971;105:1139-41.
92. McGregor M. The effort test in angina pectoris. *Am J Cardiol* 1972;30:151-2.
93. McGregor M, Becklake MR. Basic research in acupuncture analgesia. *Can Med Assoc J* 1974;110:328-9.
94. McGregor M. The coronary collateral circulation. Editorial. *Circulation* 1975;52:529-30.
95. McGregor M. Cardiology in a system of socialized medicine: The Canadian experience. *Am J Cardiol* 1975;36:560-2.
96. Anturane Reinfarction Trial Group. Sulfipyrazone in the prevention of cardiac death after myocardial infarction. *N Engl J Med* 1978;298:289-95, 333-4.
97. McGregor M, Pelletier G. Planning of specialized health facilities. *N Engl J Med* 1978;299:179-81.
98. McGregor M. Entry into life sustaining systems: resource allocation. *Annals of the Royal College of Physicians and Surgeons of Canada*. October , 1979:276-7.
99. McGregor M. Pulsus Paradoxus. *N Engl J Med* 1979;301:480-1.
100. Anturane Reinfarction Trial Group. Sulfipyrazone in the prevention of sudden death after myocardial infarction. *N Engl J Med* 1980;302:250-6.
101. Anturane Reinfarction Trial Policy Committee. The Anturane reinfarction trial: Re-evaluation of outcome. *N Engl J Med* 1982;306:1005-8.
102. McGregor M. The nitrates and myocardial ischemia. *Circulation* 1982;66:689-92.
103. Boice JL, McGregor M. Effects of resident's use of laboratory tests on hospital costs. *J Medical Ed* 1983;158:61-2.
104. McGregor M. The pathogenesis of angina pectoris and the role of nitrates in the relief of myocardial ischemia. *Am J Med* 1983;74:21-7.
105. McGregor M. Myocardial ischemia: towards better use of the CCU. *Am J Med* 1984;76:887-90.

106. Ducas J, Magder S, McGregor M. The validity of the hepatojugular reflux as a clinical test for congestive heart failure. *Am J Cardiol* 1983;52:1299-303.
107. McGregor M, Crelinsten G. Possible interactions of indomethacin and nitrates in angina pectoris. *Am J Cardiol* 1984;53:225-7.
108. McGregor M, Sheldon H, Dwyer D, et al. The role of intimal hyperplasia in arterial spasm. *Can Med Assoc J* 1984;131:329-30.
109. McGregor M. The Coronary Care Unit: a lack of consensus. *Am J Med* 1985;78: 367-8
110. McGregor M, Sniderman A. On pulmonary vascular resistance: a misinterpretation born of miscalculation. *Am J Cardiol* 1985;55:217-21
111. McGregor M. Four sins of medicine. *S A Med J* 1985;67:643-5.
112. Langleben D, Moroz LA, McGregor M, Lisbona R. Decreased half-life of Fibrinogen in primary pulmonary hypertension. *Thrombosis Res* 1985;40:577-80.
113. Mitchell G, McGregor M. The role of the university in the training of health professionals. *S A Med J* 1986;70:3-4.
114. McGregor M. Mechanisms of transient myocardial ischemia. *Can J Cardiol* 1986; (Suppl A): 53A-8A
115. Mitchell G, Mitchell D, McGregor M, Fridjohn P. Selection of medical students: are all matriculation examinations equivalent? *S A Med J* 1987;72:416-8.
116. Eidelman D, Sami M, McGregor M, Cosio MG. The effect of the combination of theophylline and salbutamol in arrhythmias in severe COPD. *Chest* 1987;91:808-12.
117. McGregor M. Apartheid and the academic boycott of South Africa. *N Engl J Med* 1987;316:(16)1022-3.
118. McGregor M. Pharmaceutical "Generosity" and the Medical Profession. *Annals of the Royal College of Physicians and Surgeons of Canada*, 1988;21:289.
119. McGregor M, Ncayiyana D. An innovative medical curriculum. *S A Med J* 1988;74:XVII-XIX
120. Silberberg JS, McGregor M. Restoration of flow in acute coronary obstructive syndromes: Consequences of different management strategies. *Can J Cardiol* 1989;5:129.
121. Myer T, Sareli P, McGregor M, et al. Mechanism underlying Kussmaul's sign in chronic constrictive pericarditis. *Am J Cardiol* 1989;64:1069-72.
122. McGregor M. Technology and the allocation of resources. *N Engl J Med* 1989;320:118-9.
123. Caro JJ, Trindade E, McGregor M. The risks of death and of severe nonfatal reactions with high- vs low osmolality contrast media: a meta-analysis. *AJR* 1991;156:825-32.
124. Kimoff RJ, Cosio MG, McGregor M. Clinical features and treatment of obstructive sleep apnea. *Can Med Assoc J* 1991; 144:689-95.
125. Caro JJ, Trindade E, McGregor M. The cost-effectiveness of replacing high-osmolality with low osmolality contrast media. *AJR* 1992; 159(4):869-74.
126. McGregor M. The reuse of cardiac pacemakers. *Can J Cardiol* 1992;8(7):697-701.
127. Roy DJ, Dickens BM, McGregor M. The choice of contrast media: medical, ethical and legal considerations. *Can Med Assoc J* 1992;147(9):1321-4.
128. Baris E, McGregor M. The reuse of hemodialysers: an assessment of safety and potential savings. *Can Med Assoc J* 1993;148(2):175-83.
129. Archer C, Levy AR, McGregor M. Value of routine preoperative chest x-rays: a meta-analysis. *Can J Anesth* 1993;40(11):1022-7.
130. Jacob R, et al. The reuse of single-use cardiac catheters: Safety, economical, ethical and legal issues. *Can J Cardiol* 1994;10 (4):413-21.
131. Levy AR, McGregor M. How has lithotripsy changed the treatment of renal stones in Quebec? *Can Med Assoc J* 1995;153(12):1729-36.
132. Boivin JF, McGregor M, Archer C. Cost effectiveness of screening for primary open angle glaucoma. *J Med Screening* 1996; 3: 154-63.
133. Jacob R, McGregor M. Assessing the impact of health technology assessments. *Internat J Technol in Health Care* 1997; 13: 68-80.
134. McGregor M. Coverage of drug costs: Reference-based pricing. *Can J Cardiol* 1998;14(5): 666-668.

135. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of over detection. *Can Med Assoc J* 1998; 159(11):1368-72.
136. McGregor M et al. Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. A Canadian consensus document. *Can Med Assoc J* 1998; 158 (3 Suppl).
137. McGregor M. The hepatitis C disaster. *Can Med Assoc J* 1998; 158(11): 1461.
138. McGregor M, Brophy JM. Use of Abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty. *Can J Cardiol* 1999(Feb); 15 (2):201-207.
139. McGregor M. Implantable Left Ventricular Assist Devices: Is it time to introduce them in Canada ? *Can J Cardiol* 2000;16(5):629-40.
140. McGregor M. The Academic Prince. *Acad. Med.* 2002;77:1221-2.
141. McGregor M. Cost-utility analysis: Use QALYs only with great caution. *Can Med Assoc J* 2003; 168:433-4
142. McGregor M. Should the implantable cardiac defibrillator be used for primary prevention of sudden death? A review of issues relevant to hospital decision making. *Can J Cardiol.* 2004;20 (12):1199-04.
143. McGregor M, Brophy J. End-user involvement in HTA development. A way to increase impact. *Int J Technol Assess in Health Care.* 2005; 21:263-7.
144. Dendukuri N, Costa V, McGregor M, Brophy J.M. Probiotic therapy for the prevention and treatment of *Clostridium difficile*-associated diarrhea: a systematic review. *CMAJ* 2005;173:167-70.
145. McGregor M. What decision makers want and what they have been getting. *Value in Health.* 2006;9(3):181-5.
146. Costa V, McGregor M, Laneuville P, Brophy JM . The Cost-Effectiveness of Stem Cell Transplantations from unrelated donors in adult patients with Leukemia. *Value in Health.* 2007;10(4):1-9.
147. McGregor M, Caro J. QALYs. Are They Helpful to Decision Makers? *Pharmacoeconomics.* 2006; 24 (10): 947-52.
148. Zanke B, Spencer PC, Culyer T, Longo C, McGregor M. Facing cancer costs. How will we afford hi-cost cancer therapies? *Oncology Exchange.* 2007; 6(1): 42-48.
149. McGregor M. Evaluation Before Acquisition: a hospital approach to decision-making. *Ontario Thoracic Revues.* 2007;19(2):1-4.
150. McGregor M. Paying for Technology: The Cost of Ignoring Opportunity Costs. *Healthcare Quarterly.* 2010. 13 (2), 90-2.
151. Caro JJ, Nord E, Siebert U, McGuire A, McGregor M, Henry D, De Pourvourvilll G, Atella V, Kolominsky-Rabas P. The efficiency frontier approach to economic evaluation of health-care interventions. *Health Econ .* 2010;Oct. 19 (10). 1117-27..
152. Xie X, Dendukuri N, McGregor M. Percutaneous Radiofrequency ablation for the treatment of hepatocellular carcinoma: A Health Technology Assessment. *Journal of Technology Assessment in Health Care.* 26:4 (2010),390-397.
153. Xie X, McGregor M, Dendukuri N.The Clinical Effectiveness of Negative Pressure Wound Therapy. A systematic review. *Journal of Wound Care,* Vol.9(11), 490 – 95.
154. Xie X. McGregor M, 532 nm KTP Laser for laryngeal lesions. A systematic review. *J Voice* 2012.[http://www.jvoice.org/article/S0892-1997\(12\)00203-2/abstract](http://www.jvoice.org/article/S0892-1997(12)00203-2/abstract)

**Book Chapters/Contributions to a collective peer reviewed work**

1. McGregor M. Pulmonary hypertension. 10th Hahnemann Symposium . Aging of the Lung, 1963.
2. McGregor M, Palmer WH. Mechanism of angina pectoris. In "Coronary Heart Disease". Eds: William Likoff and JH Moyer. Grune & Stratton, New York 1963; 17 8-18 1.
3. McGregor M. Mitral stenosis and pulmonary hypertension. In "The Theory and Practice of Auscultation". FA Davis Co, Philadelphia 1963;379-383.
4. McGregor M. Pulmonary hypertension. In "Aging of the Lung". Ed: L Cander. Grime & Stratton, New York 1964;310-321.
5. McGregor M. Hypoxia and the lung. Canadian Cardiovascular Society Conference on Oxygen Tension,1965.
6. McGregor M. The role of oxygen tension in the regulation of pulmonary blood flow. In: "Cardiovascular and Respiratory Effects of Hypoxia". Ed: D Hatcher. S. Karger, Basel 1966;287-306.
7. Fam WM, McGregor M. Studies on myocardial oxygen tension. In: "Cardiovascular and Respiratory Effects of Hypoxia". Ed: D Hatcher. S. Karger, Basel 1966.
8. Fam WM, Nakhjavan FK, Sekelj P, McGregor M. The effects of oxygen breathing, Nitroglycerin, and Dipyridamole in healthy and ischemic areas of the myocardium. In: Symposium on cardiovascular effects of hypoxia. Ed: D Hatcher. S. Karger, Basel 1966;375-90.
9. McGregor M. Drugs for the treatment of angina pectoris. In: "International Encyclopedia of Pharmacology and Therapeutics". Ed: C. Raduoco-Thomas. Pergamon Press, Oxford, Section 6, 1966;11:377-403.
10. Fam WM, McGregor M. The role of collateral circulation in evaluation of anti-anginal drugs. In: "Problems in Laboratory Evaluation of Anti-Anginal Agents". Ed: MJ Winbury. North-Holland, Amsterdam 1967;17-25.
11. McGregor M. Pharmacology of anti-anginal agents. Med Coll Virginia Quarterly 1967;3(2):77-9.
12. McGregor M. The effects of hypoxia on the pulmonary circulation. Entretien de Physio-Pathologie Respiratoire. Gauthier-Villars, Paris, 1967;7e Serie:348-54.
13. McGregor M. L'Université et les services de santé au Québec. In: Autopsie d'un système. Ed: G. Blain. Les éditions Administration et Santé 1971:59-65.
14. McGregor M. The state and the medical profession. Bull Am Coll of Surg 1971;56(9)13-15.
15. McGregor M. Le Troisième Cinquantenaire de la Faculté de Médecine de McGill. L'Union Médicale du Canada 1971;100:435-7.
16. McGregor M. The McGill Responsibility. Can Med Assoc J 1971;105:1129-232.
17. McGregor M. Les perspectives d'avenir de la médecine à McGill. L'Union Médicale du Canada 1971;101:2621-3.
18. McGregor M. Migration of medical manpower. Ed: JZ Bowers. The Josiah Macy Jr. Foundation, New York 1971, p 31-42.
19. McGregor M. Significance of myocardial flow measurement in the evaluation of the coronary patient. In: "Myocardial Blood Flow in Man". Ed: A Maseri. Minerva Med, Torino, 1972;p 287-296.
20. McGregor M, Fam WM. On the site of vasomotion in the coronary vascular bed. In:"The Study of the Systemic Coronary and Myocardial Effects of Nitrites". Ed: GG Gensini. CC Thomas, Springfield 1972;p. 323-33.
21. McGregor M. Coronary Steal. A Review. Das chronisch kranke Herz. Ed: H Roskarn and H Reindel. FK Schaltauer Verlag, Stuttgart 1973;p. 69-72.
22. McGregor M. Impact of health care legislation on the medical school. In: "International Aspects of the Provision of Medical Care". Ed: PW Kent. Oriel Press, England 1976.
23. McGregor M. Governments and medical schools. New Zealand Med J 1977;85:383-5.
24. McGregor M. Les conséquences de la "Technologie Palliative" sur les services de santé. In: "Innovation Technologique et Services de Santé". Ed: FA Roberge. Université de Montréal, Montreal 1978;p 18-21.

25. McGregor M. How to cut health care costs by 25% in the hospital. Means, consequences. In: "Painful Choices for Tomorrow: Health Care on Diminished Budgets". Ed: RS Tonks. The Eastern Canadian /American Health Conference, 1979.
26. McGregor M, Mustard JF, Ovier M, Sherry S. Eds: "Cardiovascular Actions of Sulfinpyrazone". Symposium Specialists Inc. Miami, USA, October 1980.
27. McGregor M. Hospital costs: Can they be cut? *Millbank Memorial Fund Quarterly* 1981;59:89-98.
28. McGregor M. Les services de santé: Perspectives sur les années 80. Le point de vue d'un médecin. In: Actes du 3e colloque Jean-Yves-Rivard. Les Éditions Administration et Santé, Montréal 1982; 15-22.
29. McGregor M. L'impact de la technologie sur le système des soins. In: "Traité d'Anthropologie Médicale". Eds: J. Dufresne, F. Dumont, Y. Martin. Presses de l'Université du Québec, Québec 1985:385-404.
30. McGregor M. Mechanism of nitrates in the relief of rest angina. In: "Motionitrates". Eds: GM Cohn & R Rittinghausen. Springer-Verlag, Berlin 1985:193-200.
31. Elmslie K et al. Guidelines on ethical and legal considerations in anonymous unlinked HIV seroprevalence research. *Can Med Assoc J* 1990;143(7):625-27.
32. McGregor M. Technology evaluation. Its value and its limitations. *ACMC Forum* 24:1-4, 1991.
33. McGregor M. Does bioscience threaten human integrity? In: Schering Foundation Workshop Round table discussion on bioscience and society. Ed: J.J. Cherfas. Springer. Berlin 1992.
34. McGregor M. Assessment of new technologies. In: Symposium on resource allocation in the intensive care unit. *Annals of the Royal College of Physicians and Surgeons of Canada* 1992;25(I): 55-6.
35. McGregor M. L'évaluation des technologies au Québec: Le conflit des coûts par rapport à l'efficacité et la sécurité. XHI' colloque Jean-Yves-Rivard: La gestion et l'évaluation des technologies de la santé, 1992. Montreal, Quebec. 1993:27-31.
36. McGregor M. Cholesterol and Coronary Disease: Intervention Strategies. Conseil d'évaluation des technologies de la santé du Québec. Montréal: CETS, 1993. ISBN 2-550-27185-8.
37. McGregor M. Can our health services be saved by technology evaluation. The Québec experience. *Clin Invest Med* 1994; 17;(4):334-342.
38. McGregor M. Technology evaluation in Sub-Saharan Africa. Can the Canadian experience be of use? *S A Med J* 1994;84(9):585-86.
39. McGregor M. Implementing advances in medical technology: the Canadian view. *J R Soc Med* 1995;88(526):29-30.
40. Boivin J-F, McGregor M. Le Dépistage du glaucome primitif à angle ouvert. Conseil d'évaluation des technologies de la santé du Québec. Montréal: CETS, 1995. ISBN 550-29221-9.
41. Archer C, McGregor M. Use of contrast media in Québec : a Follow-up. Conseil d'évaluation des technologies de la santé du Québec. Montréal: CETS, 1995.
42. Hanley JA, McGregor M. Le dépistage du cancer de la prostate. Conseil d'évaluation des technologies de la santé du Québec. Montréal: CETS, 1995. ISBN 2-550-2674-8.
43. McGregor M, Jacob R. Critères et processus de décision pour la couverture des médicaments couteux au Québec. Rapport préparé pour la Sous-Ministre de la Santé et des Services Sociaux. 28 Aout 1998.
44. Steering Committee, Canadian Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. M. McGregor, Editor and Chair, Steering Committee. *Can Med Assoc J* 1998; 158 (3 Suppl): S1-83.
45. McGregor M. The Ethics of Waiting. In: Do We Care? Renewing Canada's Commitment to Health. Ed Somerville M. McGill-Queen's University Press. Montreal, 1999, pp 121-4.
46. McGregor M. Implantable Left Ventricular Assist Devices: Should they be used in Québec? Conseil d'évaluation des technologies de Québec. Montréal, CETS. 2000. ISBN 2-550-35678-0
47. McGregor M. Evaluation of a safety device to prevent needlestick injuries. The Technology Assessment Unit (TAU), McGill University Health Center. Montréal. 2002. Available from: <https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Needlestick.pdf>
48. McGregor M. Should the MUHC Initiate an Antiviral Treatment Programme for Patients with Chronic Hepatitis C? The McGill University Health Centre. 2002, Oct. 8. Available from:

- [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/MUHC\\_HC.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/MUHC_HC.pdf)
49. Bourgault C, McGregor M. Should the MUHC use Mitoxantrone in the Treatment of Multiple Sclerosis? The McGill University Health Centre. 2002, Dec. 2. Available from: <https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Mitoxantrone.pdf>
50. Chen J, Penrod J, McGregor M. Should the MUHC use low-molecular-weight heparin in inpatient treatment of deep vein thrombosis with or without pulmonary embolism? The McGill University Health Centre, February 6, 2003 . Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Heparin\\_report\\_Feb.6.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Heparin_report_Feb.6.pdf)
51. McGregor M. Should the MUHC approve the use of colorectal stents? The McGill University Health Centre, March 13, 2003. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Stents\\_colorectal\\_Feb\\_2003.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Stents_colorectal_Feb_2003.pdf)
52. McGregor, M. Eprex and pure red cell aplasia. What should be MUHC policy for hemodialysis patients? The McGill University Health Centre, April 25, 2003. Available from: <https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Eprex.pdf>
53. McGregor, M. Chen, J. Use of the Implantable Cardiac Defibrillator (ICD) at the McGill University Health Centre (MUHC), September 10, 2003. Available from: <https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/icd.pdf>
54. Chen, J., McGregor, M. The Gastric Banding Procedure. An Evaluation. Technology Assessment Unit of the McGill University Health Centre. April 27, 2004. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Gastric\\_Banding\\_FINAL\\_Apr27.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Gastric_Banding_FINAL_Apr27.pdf)
55. Dendukuri N, McGregor M, Brophy J. The use of Probiotics in the Prevention and Treatment of C. Difficile Diarrhea. Technology Assessment Unit. McGill University Health Centre. December 10, 2004. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/PROBIOTICS\\_Report\\_5Final.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/PROBIOTICS_Report_5Final.pdf)
56. Costa V., Brophy J., McGregor M. Transplantation of Allogeneic Hematopoietic Stem Cells from Unrelated Donors in Adult Patients at the MUHC. Technology Assessment Unit. McGill University Health Centre. April 20, 2005. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Stem\\_Cells\\_report\\_20April2005\\_FinalVersion.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Stem_Cells_report_20April2005_FinalVersion.pdf)
57. Costa V., Brophy J., McGregor M. Vacuum-Assisted Wound Closure Therapy (V.A.C. ®) Technology Assessment Unit. McGill University Health Centre. July 11, 2005. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/VAC\\_REPORT\\_FINAL.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/VAC_REPORT_FINAL.pdf)
58. Erickson L., Costa V., McGregor M. Use of Intraoperative Neurophysiological Monitoring during Spinal Surgery. Technology Assessment Unit. McGill University Health Centre. July 7, 2005 Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/SPINAL\\_MONITORING\\_Final.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/SPINAL_MONITORING_Final.pdf)
59. Costa V, McGregor M, Brophy J. The use of mitoxantrone in the treatment of patients with multiple sclerosis. Report Update. Technology Assessment Unit. McGill University Health Center. March 16, 2006. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/mitoxantrone\\_report\\_May23FINAL.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/mitoxantrone_report_May23FINAL.pdf)
60. McGregor M, Costa V. Should the McGill University Health Centre use safety devices to reduce needlestick injuries associated with intravascular infusions? Report Update. Technology Assessment Unit. McGill University Health Centre. May 23, 2006. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/needlestick\\_update\\_May2006\\_FINAL.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/needlestick_update_May2006_FINAL.pdf)
61. Erickson L, McGregor M. Wait times at the MUHC 1. Diagnostic imaging, joint replacement, Cancer care, sight restoration, cardiac care. Technology Assessment Unit. McGill University Health Centre. September 19, 2006. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait\\_Times\\_Report\\_No\\_1\\_final.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait_Times_Report_No_1_final.pdf)
62. Erickson L, McGregor M. Wait times at the MUHC 2. Selected Divisions of the MUHC Departments of Medicine and Surgery. Technology Assessment Unit. McGill University Health Center. September 8, 2006. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait\\_Times\\_Report\\_No\\_2\\_final.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait_Times_Report_No_2_final.pdf)

63. McGregor M., Atwood CV. Wait times at the MUHC. No. 3 Fracture management. Technology Assessment Unit. McGill University Health Centre. May 4 2007 Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait\\_Time\\_Fractures\\_May2007\\_Final.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait_Time_Fractures_May2007_Final.pdf)
64. Costa V., McGregor M., Brophy J. Pulsatile machine perfusion compared to cold storage in kidney preservation. Joint Technology Assessment Unit (MUHC/CHUM). May 10, 2007 Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/machine\\_perfusion\\_May\\_10.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/machine_perfusion_May_10.pdf)
65. McGregor M., Atwood CV. Wait times at the MUHC. No 4. Diagnostic Imaging Revisited. Adult Hospitals of the MUHC. Technology Assessment Unit. McGill University Health Centre. May 4 2007. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait\\_times\\_radiology.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait_times_radiology.pdf)
66. McGregor M. The impact of TAU reports. Technology Assessment Unit. McGill University Health Centre. Feb 1,2008. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/FINAL\\_TAU\\_IMPACT\\_REPORT\\_FEB\\_2008.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/FINAL_TAU_IMPACT_REPORT_FEB_2008.pdf)
67. Atella V, Caro J, de Pouvourville G, Henry D, McGregor M, McGuire A, Nord E, Siebert U. Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System. Report prepared for IQWiG [Institute for quality and efficiency in health care] Dillenburger Straße 27. D-51105 Cologne. Jan 24 2008.
68. Xie X, Dendukuri N, McGregor M. Comparison of Coblation Tonsillectomy and Electrocautery Tonsillectomy in Paediatric Patients. Technology Assessment Unit. McGill University Health Centre. Nov 12, 2008 Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Coblation\\_ND\\_MMG\\_LFM\\_Final.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Coblation_ND_MMG_LFM_Final.pdf)
69. Caro J. (Chair), Atella V, de Pouvourville G, Henry D, McGregor M, McGuire A, Nord E, Siebert U. (Members of the IQWiG International Expert Panel) Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System ) IQWiG. Institute for Quality and Efficiency in Health Care. 2009 . Dillenburger Straße 27D-51105 Cologne. Germany.
70. Nassef M, Dendukuri N, McGregor M. L'utilisation des implants Carmustine (Gliadel Wafers) chez les patients atteints de gliome malin. Unité de l'évaluation des technologies du CUSM. Avril 2009. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/GLIADEL\\_June\\_4\\_09.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/GLIADEL_June_4_09.pdf)
71. Esfandiari S, Dendukuri N, McGregor M. Clinical efficacy and cost of Allogenic Acellular Dermal Matrix (AA DM) in implant-based breast reconstruction of post mastectomy cancer patients. Technology Assessment Unit of the McGill University Health Centre. April 20, 2009. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/DERMAMATRIX\\_FINAL\\_JUNE\\_09.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/DERMAMATRIX_FINAL_JUNE_09.pdf)
72. McGregor M. Opportunity Costs Associated with Technology Expansion in the Hospital. Technology Assessment Unit of the McGill University Health Centre. May 5, 2009 Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Budget\\_Creep\\_TAU\\_JULY\\_12\\_2009\\_FINAL.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Budget_Creep_TAU_JULY_12_2009_FINAL.pdf)
73. Lapointe A, McGregor M. La microchirurgie endoscopique transanale (TEM). DETMIS CHUM. juillet 2009. <http://www.chumtl.qc.ca/userfiles/File/PUBLICATIONS/DETMIS/La%20microchirurgie%20endoscopique%20transanale.pdf>
74. Pan I. Dendukuri N, McGregor M. Efficacy and cost-effectiveness of Collatamp-G for infection prophylaxis in cardiac surgery. Technology Assessment Unit of the McGill University Health Centre. November 30, 2009. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/COLLATAMP\\_CARDIAC\\_REPORT.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/COLLATAMP_CARDIAC_REPORT.pdf)
75. Xuanqian Xie, McGregor M .Dendukuri N, Radio-frequency ablation for the treatment of Barrett's oesophagus: A systematic review and cost analysis. Technology Assessment Unit of the McGill University Health Centre. November 12, 2009. Available from: [https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/BARRETTsESOPHAGUS\\_REPORT.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/BARRETTsESOPHAGUS_REPORT.pdf)

76. McGregor M, Esfandiari S. Transcatheter Aortic Valve Implantation (TAVI) at the MUHC: a Health Technology Assessment. Technology Assessment Unit of the McGill University Health Centre. December 15, 2009. Available from:  
[https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/TAVI\\_REPORT.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/TAVI_REPORT.pdf)
77. Xuanqian Xie, McGregor M .Dendukuri N, The use of probiotics in the prevention and treatment of *Clostridium Difficile* diarrhoea: An update. Technology Assessment Unit of the McGill University Health Centre. November 25, 2009. Available from:  
[https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/PROBIOTICS\\_REPORT.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/PROBIOTICS_REPORT.pdf)
78. Nassef M, McGregor M. The use of Matrix Coils in the Treatment of Cerebro-vascular Aneurysms: An Update. Technology Assessment Unit of the McGill University Health Centre.July 9, 2009. Available from:  
[https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/MATRIX\\_COILS\\_REPORT.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/MATRIX_COILS_REPORT.pdf)
79. Xuanqian Xie, Dendukuri N, McGregor M. Percutaneous Radio-frequency Ablation for treatment of hepatocellular carcinoma. Technology Assessment Unit of the McGill University Health Centre. July 30, 2009. Available from:  
[https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/RFA\\_and\\_Liver\\_Cancer\\_FINAL.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/RFA_and_Liver_Cancer_FINAL.pdf)
80. Pan I, McGregor M. Efficacy, safety and cost of ultrafiltration for the management of acute decompensated heart failure. Technology Assessment Unit of the MUHC. May 31, 2010. Available from:  
[https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Ultrafiltration\\_FINAL.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Ultrafiltration_FINAL.pdf)
81. Xie X, McGregor M. Negative Pressure Wound Therapy ( NPWT). (Update of report 19). Technology Assessment Unit of the MUHC. June 25, 2010. Available from:  
[https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/NPWT\\_FINAL.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/NPWT_FINAL.pdf)
82. Pan I, Dendukuri N, McGregor M. Argon beam coagulation in orthopaedic, and thoracic surgery at the MUHC: a brief report. Technology Assessment Unit of the MUHC. November 26, 2010. Available from:  
[https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Argon\\_Beam\\_Coagulation\\_FINAL.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Argon_Beam_Coagulation_FINAL.pdf)
83. Sinclair A, McGregor M, Xie X. Aortic valve bypass (apicoaortic conduit) in adult degenerative aortic stenosis. Technology Assessment Unit, MUHC. February 2011. Available from:  
[https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/AorticValveBypass\\_FINAL.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/AorticValveBypass_FINAL.pdf)
84. Dendukuri N, Xie X, McGregor M. Fiducial markers for improving treatment margins in radiotherapy for prostate cancer. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); Mini HTA:2011 Jun 16. Report no. 52. 7 p. Available from:  
[https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Muhc\\_tau\\_MiniHTA\\_2011\\_52\\_FdMk.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Muhc_tau_MiniHTA_2011_52_FdMk.pdf)
85. McGregor M, Sinclair A. Drug eluting stents: What should be the indications for their use at the MUHC? Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2011 Dec 20. Report no. 55. 29 p. Available from:  
[https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc\\_tau\\_2011\\_55\\_destents.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2011_55_destents.pdf)
86. Xie X, Nicolau I, McGregor M, Dendukuri N. Subglottic secretion drainage endotracheal tubes for prevention of ventilator-associated pneumonia. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2011 Dec 21. Report no. 56. 38 p. Available from:  
[https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc\\_tau\\_2011\\_56\\_SSD.pdf](https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2011_56_SSD.pdf)
87. Xie X, McGregor M. 532 nm KTP Laser for Vocal Fold Surgery. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 April 24.. Report no. 61 16 p. Available from: [http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc\\_tau\\_2012\\_61\\_ktp\\_a.pdf](http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_61_ktp_a.pdf)
88. Xie X, McGregor M. Video Capsule Endoscopy for Obscure GI Bleeding and Crohn's Disease (Update of Report 7). Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 June 13. Report no. 60. 24 p. Available from:  
[http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc\\_tau\\_2012\\_60\\_vce.pdf](http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_60_vce.pdf)
89. Sinclair A, Dendukuri N, McGregor M. Use of serum calcitonin levels in treatment decisions for adult patients in the intensive care unit. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 , June 13. Report no. 62. 20 p. Available from:  
[http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc\\_tau\\_2012\\_62\\_procalcitonin.pdf](http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_62_procalcitonin.pdf)

90. Nicolau I, Pan I, Xie X, McGregor M, Dendukuri N. Drotregin Alfa (Activated) in Severe Sepsis: a systematic review of observational studies. (Update of report 29). Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 , July 25. Report no. 58 12 p. Available from:  
[http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc\\_tau\\_2012\\_58\\_sepsis\\_a.pdf](http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_58_sepsis_a.pdf)
91. McGregor M, Xie X. Hyaluronic Acid Fat Graft Myringoplasty or Epidisk Tymponoplasty (ET). Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 , Aug 29. Report no. 69. 5 p. Available from:  
[http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc\\_tau\\_2012\\_69\\_epidisk.pdf](http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_69_epidisk.pdf)
92. McGregor M. The Impact of Reports of the Technology Assessment Unit of de McGill University Health Centre. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 , Sept 13. Report no. 65. 5 p. Available from:  
[http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc\\_tau\\_2012\\_65\\_impact.pdf](http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_65_impact.pdf)
93. McGregor M. The Hybrid Operating Room. Should one be available for Cardiovascular-Thoracic procedures in the MUHC? Montreal (Canada): Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 Nov 6. Report no. 67. 12 p. Obtainable from:  
<http://www.mcgill.ca/tau/>
94. Xuanqian X., Dendukuri N., McGregor M. Single-dose Intraoperative Radiotherapy Using Intrabeam® for Early-stage Breast cancer: A Health Technology Assessment. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012, Report no. 63, 26p.
95. Nicolau I, Xie X, McGregor M, Dendukuri N. Evaluation of Acellular Dermal Matrix for Breast Reconstruction: An Update. Montreal (Canada): Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 Nov 15. Report no. 59. 39 p.

